Celsee Inc., an Ann Arbor company that offers instruments and consumables for the isolation, detection, and analysis of single cells, today announced it has been acquired by Bio-Rad Laboratories Inc. in California. Terms of the deal were not disclosed.
Celsee’s Genesis System offers a scalable and efficient approach to analyze single cells. Scientists can interpret cellular behavior and collect cell-based information for improved study. The system can scale from hundreds to millions of cells for genomic and proteomic applications and can enrich or monitor circulating tumor cells to determine disease progression and therapeutic response.
“We are pleased to have Celsee join Bio-Rad,” says Norman Schwartz, president and CEO of Bio-Rad. “Their innovative products and technologies will extend our reach into the rapidly growing world of precision medicine and single-cell analysis, both of which offer enhanced insight into disease, diagnosis, and treatment.”
Founded in 2011, Celsee’s customers include research, translational, and biopharma laboratories worldwide.
Bio-Rad develops, manufactures, and markets a broad range of products and solutions for the life science research and clinical diagnostic markets. It serves universities, research institutions, hospitals, public health, and commercial laboratories, as well as the biotechnology pharmaceutical, and food safety industries. It was founded in 1952 and serves more than 150,000 customers globally. It employs more than 8,000 people worldwide.